The Ledger

2.28 billion dollars: that is the gap between what Wall Street expected Molina Healthcare to earn in 2026 and what the insurer actually guided to, and it wiped out an earnings beat within minutes of the numbers landing. Molina reported second-quarter 2026 GAAP earnings of 1.19 dollars a diluted share and adjusted earnings of 1.51 dollars a share, topping analyst estimates of roughly 1.39 to 1.40 dollars, on premium revenue of about 10.2 billion dollars and total revenue of about 10.87 billion dollars, as membership slipped to approximately 4.9 million as of June 30, 2026. The company raised its full-year 2026 adjusted earnings guidance floor to at least 5.25 dollars a share from 5.00 dollars, but held full-year revenue guidance near 42 billion dollars, about 2.28 billion dollars below the roughly 44.28 billion dollars analysts wanted, and shares fell as much as 9.2 percent in premarket trading. Chief executive Joseph Zubretsky called 2026 the “trough year” for Medicaid pretax margins, saying the imbalance between Medicaid rates and medical cost trend “appears to have stabilized,” while guidance still absorbs a 1.50 dollar per share hit from the new Florida Medicaid contract launching in the fourth quarter and a 1.00 dollar per share hit from exiting its traditional Medicare Advantage Prescription Drug product for 2027. Confidence: High on the reported figures, since they come from Molina’s own SEC filing; Medium on the exact scale of the stock move at any given moment, since premarket swings often narrow by the opening bell. Sources: Molina Healthcare’s Form 8-K, second-quarter 2026 earnings release, U.S. Securities and Exchange Commission, Molina Healthcare shares slide as forecast weighs on results, Trading Pedia.

1.10 to 1.25 dollars: that is the full-year loss per share Community Health Systems now expects for 2026, a reversal for a hospital chain that was solidly profitable a year ago. Community Health Systems reported second-quarter 2026 net income attributable to stockholders of 70 million dollars, or 0.51 dollars a diluted share, down from 282 million dollars, or 2.09 dollars a share, in the second quarter of 2025; excluding items, the adjusted result was a net loss of 0.19 dollars a share versus a 0.05 dollar loss a year earlier. Net operating revenues fell 9.8 percent to 2.825 billion dollars from 3.133 billion dollars, though same-store revenue rose 2.4 percent, and adjusted EBITDA fell to 330 million dollars from 380 million dollars; management pointed to divestitures, an unfavorable payor-mix shift and higher medical specialist fees, partly offset by higher same-store admissions, which rose 1.9 percent. The company has divested nine hospitals so far in 2026, and it now guides full-year 2026 revenue to 11.4 to 11.6 billion dollars, adjusted EBITDA to 1.3 to 1.375 billion dollars, and diluted loss per share to 1.10 to 1.25 dollars; shares fell more than 8 percent in after-hours trading. Confidence: High, since the figures come directly from the company’s own SEC filing. Sources: Community Health Systems’ Form 8-K, second-quarter 2026 earnings release, U.S. Securities and Exchange Commission, Community Health Systems misses on Q2 earnings, revenue, Fierce Healthcare.

5.5 million dollars: that is the size of the Medicaid recoupment dispute that nearly shut down a Mississippi Delta hospital last year, and on August 1 the state’s only academic medical center takes the hospital over completely, wiping out its debt in the process. A federal bankruptcy judge approved a plan July 16, 2026 for the city of Greenwood and Leflore County to donate the 25-bed Greenwood Leflore Hospital to the University of Mississippi Medical Center, effective August 1, 2026, when the facility will be renamed UMMC Greenwood; UMMC will assume the hospital’s outstanding Medicaid liabilities and deferred maintenance costs, resolving a crisis rooted in a 5.5 million dollar Medicaid recoupment demand from June 2025 that had put the hospital’s ability to make payroll at risk. About 400 people currently work at the hospital; roughly 40 will stay on to wind down its corporate affairs while others transition to Greenwood or other UMMC locations, after the hospital already cut 86 jobs in April 2026, and the hospital’s Itta Bena clinic closes July 31 even as emergency, surgical, skilled-nursing and cancer care continue uninterrupted elsewhere. The hospital was losing an estimated 7 to 9 million dollars a year even before the pandemic, and the takeover ends a saga that stretches back nearly four years to when an earlier UMMC deal collapsed. Confidence: High on the court approval, takeover date and financial history, since multiple Mississippi outlets independently confirm the bankruptcy court’s order and the hospital’s own disclosures; Medium on the precise post-transition staffing count, since final placement decisions were still being finalized as this issue went to press. Sources: UMMC to take over Greenwood Leflore Hospital Aug. 1, Mississippi Today, UMMC to take over Greenwood Leflore Hospital Aug. 1, DeSoto County News.

1.8 billion dollars: that is what a French software giant is paying for the compliance platform that already processes safety reports on 12 million patients a year for half the world’s 50 biggest drugmakers. Dassault Systèmes announced July 23, 2026 a definitive agreement to acquire ArisGlobal, an AI-native enterprise compliance platform used by more than 200 life-sciences customers, including half of the top 50 global biopharma companies plus biotech, medtech, contract research and health-authority clients, for approximately 1.8 billion dollars in cash at closing plus up to 200 million dollars more tied to multiyear AI-revenue milestones. ArisGlobal’s regulated platform processes more than 12 million patient safety reports a year and sits inside customers’ pharmacovigilance and regulatory operations, in a compliance software market Dassault sizes at 7.5 billion dollars by 2030; the all-cash deal, funded from Dassault’s existing cash, is expected to close in the second half of 2026 pending regulatory approval, and the company says it will be accretive to both revenue growth and earnings per share in its first year. Confidence: High, since the terms come directly from Dassault’s own announcement. Source: Dassault Systèmes to acquire ArisGlobal, Dassault Systèmes newsroom.

FRONTIER SCAN: 16 billion dollars: that is what the three companies that distribute nearly every drug in America have spent buying up physician practices since 2013, and the pace has only accelerated. Cardinal Health, Cencora and McKesson, the wholesalers that together move the large majority of pharmaceuticals distributed in the United States, have collectively spent more than 16 billion dollars acquiring or taking stakes in management services organizations that run physician practices, concentrated mostly in oncology, gastroenterology, ophthalmology and urology, with most of that spending landing between 2023 and 2025, according to industry analyst Drug Channels. The latest and largest example: Cencora completed its takeover of the remaining stake in OneOncology, a national community-oncology network, on February 2, 2026 for approximately 4.6 billion dollars in cash, after a December 2025 agreement that valued the OneOncology enterprise at 7.4 billion dollars. The strategic logic, per Drug Channels: ownership locks a wholesaler’s own distribution and group-purchasing volume into practices it controls, blocks drugmakers from selling directly to those practices, and gives the wholesaler visibility into which biosimilar or brand drug gets prescribed, all layered on top of higher-margin clinical revenue that a thin-margin distribution business does not generate on its own. For hospitals and independent practices competing for the same specialists, it is a new kind of consolidator, one that now owns both the supply chain feeding the exam room and the practice itself. Confidence: High on the cumulative spending figure and the OneOncology deal terms, since both are corroborated by primary company announcements and a specialist trade analyst; Medium on the market-share and strategic-rationale framing, since that synthesis comes from one analyst rather than the companies’ own stated strategy. Sources: The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices, Drug Channels, Cencora Accelerates OneOncology Acquisition, Cencora newsroom.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
ArisGlobal	Dassault Systèmes	Life sciences AI compliance and pharmacovigilance software	Approximately $1.8 billion cash plus up to $200 million contingent consideration	Dassault Systèmes to acquire ArisGlobal, Dassault Systèmes newsroom
BioLife Solutions, Inc.	Repligen Corporation	Cell therapy biopreservation media and cell-processing tools	$31.00/share ($11.25 cash plus stock), approximately $1.5 billion enterprise value	Repligen to Acquire BioLife Solutions, Repligen Corporation
Avanos Medical, Inc. (shareholder approval)	American Industrial Partners	Medtech, pain management, respiratory and specialty nutrition devices	$25.00/share cash, approximately $1.272 billion; approved by 99.75% of votes cast	Avanos Medical stockholders approve acquisition, StockTitan / SEC Form 8-K

Molina Healthcare and Community Health Systems both reported today. Universal Health Services reports July 27, Centene around July 28, Boston Scientific July 29, Humana and Privia Health both around July 29 to August 6, and Cigna July 30.